SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing extreme volatility and a sharp sell-off following its recent IPO, fueled by concerns over high valuation, impending share lockup expirations, and a rumored merger with Tesla. The community is deeply polarized, with many retail investors expressing frustration over being 'bag holders' while bears and active traders discuss aggressive short positions as they anticipate further price discovery.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing heightened volatility as investors debate the impact of potential government contract losses in Europe against strong enterprise AI adoption and solid fundamentals. The community remains deeply divided, with bears emphasizing valuation concerns and technical breakdowns, while bullish investors highlight the company's long-term role as a foundational layer for defense-oriented AI infrastructure.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively position ahead of its earnings report, fueled by a new strategic partnership with Anthropic and multiple analyst price target hikes. The community is sharply divided between bulls betting on a structural AI memory supercycle and skeptics warning of a bubble, with heavy activity in short-dated options reflecting high anticipation of post-earnings volatility.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following the signing of executive orders to accelerate the federal government's quantum computing efforts, with the company emerging as a central beneficiary of the initiative. Community sentiment is mixed as investors weigh the potential for long-term government-backed growth against concerns over technical performance and broader software sector volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant community attention as investors position for imminent long-term clinical trial results, which many view as a pivotal catalyst for a potential market re-rating or strategic acquisition. Discussions are currently dominated by the high institutional ownership, anticipation of data readouts for multiple pipeline indications, and the strategic value of the company's asset as a potential best-in-class treatment in the inflammatory skin disease market.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point for intense debate as investors weigh the stock's high dividend yield and activist-driven buyout potential against concerns over declining foot traffic and broader restaurant sector weakness. The community is deeply divided between long-term holders betting on a short squeeze or take-private deal and skeptics worried about the company's fundamental performance and high short interest.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet Inc. Class A is trending as market participants debate the long-term impact of high AI capital expenditures alongside recent departures of key DeepMind talent. The stock is facing significant volatility as investors weigh the company's aggressive infrastructure buildout against concerns over AI monetization and increased competitive pressure.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors digest high-profile departures of key AI research talent, fueling concerns about the company's competitive edge in the intensifying artificial intelligence race. While the community is actively debating the significance of this "brain drain" versus the resilience of Alphabet's core business and long-term valuation, many are using the pullback as a buying opportunity, viewing the decline as a temporary reset rather than a structural failure.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing significant momentum and investor interest driven by a major $500 million underwritten public offering, which has sparked heated debate within the community regarding potential dilution versus the company's long-term growth potential. While some investors are actively shorting the stock citing historical dilution concerns, others are holding firm, banking on the company's late-stage clinical progress and the broader positive sentiment surrounding the psychedelic therapeutics sector.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant community attention driven by a new national quantum initiative and potential future collaboration in the space sector. Investors remain highly focused on long-term potential and institutional positioning, with many discussing the stock's role in critical government-backed infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on...

Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh

Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.

MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans

Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Investors need to pay close attention to HALO stock based on the movements in the options market lately. 

Company News for May 13, 2026

Companies In The News Are: SPG, HIMS, NOVT, HALO.

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE PR Newswire SAN DIEGO, May 11, 2026 Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics Inc.

HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$68.99
Prev Close	$68.55
Open	$69.34
Dividend Yield	0.00%
50-Day Moving Average	$67.86
Beta	0.70
Avg. Volume	1.88M
PE Ratio	24.65

52-Week High	$82.22
52-Week Low	$51.06
Market Capitalization	$8.13B
EPS (Annual)	$2.56
Price to Book	36.99
Revenue Per Employee	$3.3M

Feed

News

Sentiment

Earnings

Fundamentals

Info

HALOHalozyme Therapeutics Inc.

Latest HALO News